Biotronik reports positive data from Orsiro Hybrid stent trial

Biotronik has reported positive data from a clinical study that demonstrates the strong performance of its Orsiro Hybrid drug-eluting stent.

The device was recently evaluated in a study called Bioflow-II, which assessed the safety and efficacy of Orsiro compared to Abbott's Xience Prime in the treatment of heart disease patients.

It was shown that Biotronik's device was able to meet its primary efficacy endpoint by delivering a non-inferior performance to the Abbott product, offering low rates of myocardial infarction and revascularisation without causing stent thrombosis.

Other benefits of the stent included its low strut thickness and good deliverability, advantages that have now been proven among a large and complex patient population.

Alain Aimonetti, vice-president of sales and business development for Biotronik's vascular intervention division, said: "The exciting addition of the Orsiro Hybrid DES allows us to offer the world's most advanced product portfolio for vascular intervention and paves the way for the drug-eluting absorbable scaffold we are developing."

This comes after the company last month reported positive data from a study of its Passeo-18 Lux Paclitaxel Releasing Balloon for the treatment of femoropopliteal lesions.